Credit Suisse analyst Vamil Divan maintained a Hold rating on Bristol Myers (BMY) yesterday and set a price target of $59. The company’s shares closed yesterday at $53.64.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -3.2% and a 42.9% success rate. Divan covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Aimmune Therapeutics, and Johnson & Johnson.
Bristol Myers has an analyst consensus of Hold, with a price target consensus of $59.50.
See today’s analyst top recommended stocks >>
Based on Bristol Myers’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $5.69 billion and net profit of $1.9 billion. In comparison, last year the company earned revenue of $5.25 billion and had a net profit of $845 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
